Profile data is unavailable for this security.
About the company
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells. The Company's platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its two oncology drug product candidates, CUE-101 and CUE-102, are exemplary programs from the interleukin 2 (IL-2) based CUE-100 series, and are representative of the HLA-A02 allele, which is prevalent in the United States and western European territories. CUE-101 HLA-A02 is engineered for the treatment of human papillomavirus positive, head and neck squamous cell carcinoma (HNSCC). CUE-102 HLA-A02, targeting Wilms' Tumor 1 protein, an oncofetal antigen known to be over-expressed in more than 20 different cancers.
- Revenue in USD (TTM)7.02m
- Net income in USD-49.97m
- Incorporated2014
- Employees53.00
- LocationCue Biopharma Inc40 Guest StreetBOSTON 02135United StatesUSA
- Phone+1 (617) 949-2680
- Fax+1 (302) 655-5049
- Websitehttps://www.cuebiopharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ImmuCell Corp | 21.28m | -3.90m | 31.72m | 74.00 | -- | 1.28 | -- | 1.49 | -0.5030 | -0.5030 | 2.75 | 3.18 | 0.494 | 2.29 | 9.03 | 269,401.50 | -9.05 | -5.16 | -9.97 | -5.53 | 27.55 | 40.04 | -18.31 | -12.64 | 1.00 | -8.14 | 0.3204 | -- | -5.90 | 9.72 | -131.56 | -- | -1.39 | -- |
Lipocine Inc | 4.71m | -8.97m | 31.82m | 17.00 | -- | 1.32 | -- | 6.75 | -1.71 | -1.71 | 0.8889 | 4.51 | 0.1585 | -- | 67.70 | 277,138.80 | -30.16 | -39.32 | -32.00 | -45.87 | -- | -- | -190.35 | -442.26 | -- | -- | 0.00 | -- | -670.16 | -- | -51.99 | -- | -- | -- |
Alterola Biotech Inc | 0.00 | -2.37m | 32.28m | 1.00 | -- | -- | -- | -- | -0.0023 | -0.0023 | 0.00 | -0.001 | 0.00 | -- | -- | 0.00 | -39.41 | -- | -55.31 | -- | -- | -- | -- | -- | 0.002 | -- | -- | -- | -- | -- | -14.64 | -- | -- | -- |
LianBio - ADR | 0.00 | -87.98m | 32.53m | 163.00 | -- | 0.1594 | -- | -- | -0.8195 | -0.8195 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -28.62 | -- | -35.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 43.82 | -- | -- | -- |
Quince Therapeutics Inc | 0.00 | -30.28m | 32.84m | 32.00 | -- | 0.4427 | -- | -- | -0.7599 | -0.7599 | 0.00 | 1.72 | 0.00 | -- | -- | 0.00 | -23.97 | -42.72 | -25.27 | -46.06 | -- | -- | -- | -- | -- | -- | 0.1542 | -- | -- | -- | 39.25 | -- | -5.47 | -- |
Neurobo Pharmaceuticals Inc | 0.00 | -16.58m | 33.58m | 8.00 | -- | 1.99 | -- | -- | -3.26 | -3.26 | 0.00 | 2.05 | 0.00 | -- | -- | 0.00 | -68.36 | -95.57 | -108.01 | -135.64 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.72 | -- | 75.54 | -- |
Cue Biopharma Inc | 7.02m | -49.97m | 33.86m | 53.00 | -- | 1.13 | -- | 4.82 | -1.07 | -1.07 | 0.1495 | 0.6175 | 0.1035 | -- | 8.80 | 132,452.80 | -73.69 | -57.45 | -96.35 | -68.41 | -- | -- | -711.84 | -810.87 | -- | -- | 0.1935 | -- | 340.88 | 36.88 | 4.30 | -- | -- | -- |
Immuneering Corp | 0.00 | -54.18m | 34.10m | 65.00 | -- | 0.4332 | -- | -- | -1.86 | -1.86 | 0.00 | 2.65 | 0.00 | -- | -- | 0.00 | -55.37 | -- | -58.58 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -5.86 | -- | -- | -- |
Xilio Therapeutics Inc | 0.00 | -70.96m | 34.52m | 73.00 | -- | 1.25 | -- | -- | -2.57 | -2.57 | 0.00 | 0.7474 | 0.00 | -- | -- | 0.00 | -73.11 | -- | -96.98 | -- | -- | -- | -- | -- | -- | -144.29 | 0.00 | -- | -- | -- | 13.40 | -- | -- | -- |
Mira Pharmaceuticals Inc | 0.00 | -12.36m | 34.88m | 3.00 | -- | 11.05 | -- | -- | -0.8276 | -0.8276 | 0.00 | 0.2136 | 0.00 | -- | -- | 0.00 | -587.64 | -- | -1,721.90 | -- | -- | -- | -- | -- | -- | -2.63 | 0.00 | -- | -- | -- | -69.77 | -- | -- | -- |
Unicycive Therapeutics Inc | 0.00 | -37.82m | 34.99m | 14.00 | -- | -- | -- | -- | -1.26 | -1.26 | 0.00 | 0.5779 | 0.00 | -- | -- | 0.00 | -92.81 | -218.20 | -221.58 | -609.54 | -- | -- | -- | -3,877.49 | -- | -- | 0.00 | -- | -29.02 | -- | -73.95 | -- | -- | -- |
Reviva Pharmaceuticals Holdings, Inc. | 0.00 | -40.09m | 35.04m | 15.00 | -- | -- | -- | -- | -1.60 | -1.60 | 0.00 | -0.0482 | 0.00 | -- | -- | 0.00 | -303.75 | -- | -1,499.90 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -38.92 | -- | -- | -- |
Acurx Pharmaceuticals Inc | 0.00 | -16.05m | 35.17m | 4.00 | -- | 5.83 | -- | -- | -1.17 | -1.17 | 0.00 | 0.3807 | 0.00 | -- | -- | 0.00 | -194.65 | -- | -283.87 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.55 | -- | -- | -- |
IGC Pharma Inc | 1.35m | -13.00m | 35.40m | 67.00 | -- | 4.26 | -- | 26.32 | -0.2168 | -0.2168 | 0.0229 | 0.1098 | 0.0993 | 0.292 | 18.42 | 20,074.63 | -96.01 | -42.46 | -113.83 | -46.07 | 54.50 | 20.95 | -966.54 | -730.00 | 0.9252 | -- | 0.0188 | -- | 47.64 | -23.45 | -12.98 | -- | 53.72 | -- |
Mink Therapeutics Inc | 0.00 | -20.59m | 35.83m | 31.00 | -- | -- | -- | -- | -0.5964 | -0.5964 | 0.00 | -0.585 | 0.00 | -- | -- | 0.00 | -175.32 | -- | -3,661.37 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 19.77 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Bleichroeder LPas of 31 Mar 2024 | 2.76m | 5.66% |
Slate Path Capital LPas of 31 Mar 2024 | 2.40m | 4.94% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 2.21m | 4.55% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 2.08m | 4.27% |
Park City Capital LLCas of 05 Jun 2024 | 1.00m | 2.06% |
Geode Capital Management LLCas of 31 Mar 2024 | 838.53k | 1.72% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 759.80k | 1.56% |
Robertson Stephens Wealth Management LLC (Invt Mgmt)as of 31 Mar 2024 | 478.50k | 0.98% |
Dimensional Fund Advisors LPas of 31 Mar 2024 | 381.73k | 0.79% |
Millennium Management LLCas of 31 Mar 2024 | 362.09k | 0.74% |